> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Determines Regulatory Review Period for Repatha
- URL: https://www.fdaweb.com/fda-determines-regulatory-review-period-for-repatha/
- Published: 2016-10-19T12:00:00.000Z
- Updated: 2026-09-14T21:40:45.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5137124

*Federal Register* Notice: FDA has determined the regulatory review period for Amgen’s Repatha (evolocumab) for patent extension purposes. The agency has calculated the regulatory review period as 2,267 days. Of this time, 1,901 days occurred during the testing phase of the regulatory review. To view this notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2016-10-19/pdf/2016-25221.pdf?ref=fdaweb.com).